Abstract: Poster Presentations |

Clinical evaluation of patients with acute exacerbation of chronic bronchitis treated emperically with telithromycin FREE TO VIEW

Abdalla Abu Hussein, MBBS*; Abdel-Rehim Ads, MD; Manal El-Hamamsy, MD
Author and Funding Information

Tanta Int’l Cardiothoracic Vascular Center, Tanta, Egypt


Chest. 2004;126(4_MeetingAbstracts):846S. doi:10.1378/chest.126.4_MeetingAbstracts.846S
Text Size: A A A
Published online


PURPOSE:  Acute exacerbation of chronic bronchitis (AECB) is characterized by increase in cough and worsening of dyspnoea due to, in some cases, bacterial infection. There is always a need to develop first line antimicrobial agents that cover major respiratory pathogens, with low potential to select for resistance, favorable safety and efficacy profiles, and convenient dosing regimen. Objective: To evaluate the outcome of treating AECB patients empirically with Telithromycing 800 mg once daily for 5 days.

METHODS:  Design: Open, prospective. Patients: Male and females aged 18–65 years, identified with AECB, who have not had antibiotics within 14 days before enrollment. Methods: Test of cure (TOC) was defined as disappearance of signs and symptoms of AECB with no requirement for further treatment with antibiotics. Adverse events, including abnormal laboratory values, were monitored, recorded and analyzed.

RESULTS:  Two hundred and fifty three patients were enrolled. After 5 days of treatment, the clinical outcome was 85% cure in the per-protocol (PP) patients and 80% in intent-to-treat (ITT) analysis. The cure rates increased after 10 days of treatment to 98% and 90% in the PP and ITT analysis respectively. The main adverse event was gastric upset. Nonetheless, all adverse events were of mild to moderate intensity and were easily alleviated with symptomatic intervention.

CONCLUSION:  The empiric treatment with Telithromycin for AECB patients appears to be safe and efficacious.

CLINICAL IMPLICATIONS:  The results of this work support those found elsewhere in the literature and the FDA results on Telithromycin in the AECB indication.

DISCLOSURE:  A. Abu Hussein, None.

Wednesday, October 27, 2004

12:30 PM- 2:00 PM




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543